argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships
06 Outubro 2020 - 3:00AM
- New
partnerships with Chugai and the Clayton Foundation for Research
provide access to innovative antibody engineering technologies
-
Extension of Halozyme collaboration supports long-term commitment
to subcutaneous delivery options for patients
October 6, 2020 Breda, the Netherlands /
Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases and cancer, today
announced the expansion of its technology capabilities in antibody
engineering through new partnerships with Chugai and the Clayton
Foundation. The Company is also broadening its collaboration with
Halozyme to enable subcutaneous delivery for three additional
current or future argenx product candidates. Through these
partnerships, argenx gains access to innovative technologies to
advance its differentiated pipeline and strengthen its position as
a leader in immunology.
“Our Immunology Innovation Program, through
which we partner with leading academic researchers, has been
foundational in building our pipeline. In keeping with our
commitment to expand and strengthen this program, we continue to
make investments in our portfolio of antibody technologies. These
new partnerships are a key part of the strategy to broaden our
capabilities in antibody engineering in order to address new
targets and develop first-in-class medicines for patients who need
them,” commented Hans de Haard, Ph.D., Chief Scientific Officer of
argenx. “Additionally, we announced the extension of our
collaboration with Halozyme to secure our ability to offer
subcutaneous delivery of current and future pipeline candidates. We
are on a mission to improve the lives of people suffering from
severe autoimmune diseases and cancer and believe that this
long-term collaboration will allow us to reach the greatest number
of patients.”
New Antibody Engineering Research
Agreements
argenx has entered into two new research
agreements to broaden its antibody engineering capabilities.
Through these agreements, argenx can access world-class Fc
engineering technologies to expand the therapeutic properties of
future antibody candidates that emerge from its Immunology
Innovation Program. The technologies will complement argenx’s
current portfolio of Fc engineering technologies (NHANCE®, ABDEG™,
POTELLIGENT®) and enable the Company to further differentiate and
expand its pipeline of antibody candidates.
- argenx and Chugai have entered into a research license and
option agreement under which argenx may access Chugai’s SMART-Ig®
(“Recycling Antibody” and part of “Sweeping Antibody” technology)
and ACT-Ig® (Antibody half-life extending technology).
- argenx and the Clayton Foundation have entered into a
non-exclusive research agreement under which argenx may access the
Clayton Foundation’s proprietary DHS mutations to extend the serum
half-life of therapeutic antibodies.
Expansion of Access to Halozyme’s
ENHANZE® Technology
argenx and Halozyme are expanding the existing
global collaboration and license agreement that was signed in
February 2019. Under the newly announced expansion, argenx gained
the ability to access Halozyme’s ENHANZE® drug delivery technology
for three additional exclusive targets upon nomination bringing the
total to six potential targets under the collaboration. To date,
two targets have been nominated including the human neonatal Fc
receptor FcRn and complement component C2.
ENHANZE® has demonstrated across five
FDA-approved products the ability to remove traditional limitations
on the volume of biologics that can be delivered subcutaneously,
potentially shortening drug administration time, reducing
healthcare practitioner time, and offering additional flexibility
and convenience for patients.
For more information about innovation at argenx,
please visit the Company’s website at
www.argenx.com/innovation.
About argenxargenx is a global
immunology company committed to improving the lives of people
suffering from severe autoimmune diseases and cancer. Partnering
with leading academic researchers through its Immunology Innovation
Program (IIP), argenx is translating immunology breakthroughs into
a world-class portfolio of novel antibody-based medicines in early
and late stages of clinical development. argenx is evaluating
efgartigimod in multiple serious autoimmune diseases, and
cusatuzumab in hematological cancers in collaboration with Janssen.
argenx is also advancing several earlier stage experimental
medicines within its therapeutic franchises. argenx has offices in
Belgium, the United States and Japan. For more information, visit
www.argenx.com and follow us on LinkedIn at
https://www.linkedin.com/company/argenx/.
Forward-looking Statements
The contents of this announcement include statements that are,
or may be deemed to be, “forward-looking statements.” These
forward-looking statements can be identified by the use of
forward-looking terminology, including the terms “believes,”
“estimates,” “anticipates,” “expects,” “intends,” “may,” “will” or
“should” and include statements argenx makes concerning the
intended benefits of its partnerships and the therapeutic potential
of its product candidates. By their nature, forward-looking
statements involve risks and uncertainties and readers are
cautioned that any such forward-looking statements are not
guarantees of future performance. argenx’s actual results may
differ materially from those predicted by the forward-looking
statements as a result of various important factors, including
argenx’s expectations regarding its the inherent uncertainties
associated with competitive developments, preclinical and clinical
trial and product development activities and regulatory approval
requirements; argenx’s reliance on collaborations with third
parties; estimating the commercial potential of argenx’s product
candidates; argenx’s ability to obtain and maintain protection of
intellectual property for its technologies and drugs; argenx’s
limited operating history; and argenx’s ability to obtain
additional funding for operations and to complete the development
and commercialization of its product candidates. A further list and
description of these risks, uncertainties and other risks can be
found in argenx’s U.S. Securities and Exchange Commission (SEC)
filings and reports, including in argenx’s most recent annual
report on Form 20-F filed with the SEC as well as subsequent
filings and reports filed by argenx with the SEC. Given these
uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this
document. argenx undertakes no obligation to publicly update or
revise the information in this press release, including any
forward-looking statements, except as may be required by law.
For further information, please contact:
Beth DelGiacco, Vice President, Investor Relations (US)+1 518
424 4980bdelgiacco@argenx.com
Joke Comijn, Director Corporate Communications & Investor
Relations (EU)+32 (0)477 77 29 44+32 (0)9 310 34
19jcomijn@argenx.com
Argen X (EU:ARGX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Argen X (EU:ARGX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024